Remove 2027 Remove Compounding Remove Labelling
article thumbnail

BizDateUp leads USD 1 million pre-IPO round in pharma packaging startup Sorich

Express Pharma

The investment will also help upgrade existing machinery, particularly for the production of high-margin items like Heat Transfer Labels (HTL). billion by 2027, growing at a compound annual growth rate (CAGR) of approximately 14.9 Sorich aims to deliver health-enhancing packaging solutions through its innovations.

Packaging 105
article thumbnail

CD19 CAR-T agents to boost blood cancer market

European Pharmaceutical Review

Breyanzi will exhibit the largest compound annual growth rate (CAGR) at 30 percent, compared to Yescarta’s CAGR of 9 percent. Breyanzi sales will also be supplemented by the anticipated approval in chronic lymphocytic leukemia (CLL) in 2027, making it the first and only currently marketed CD19 CAR-T agent to penetrate the CLL market.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Endometriosis market projected to grow at a CAGR of 10% between 2020 and 2030

Pharmaceutical Technology

The endometriosis market is expected to grow from $1.05bn in 2020 to $2.72bn in 2030 at a compound annual growth rate (CAGR) of 10.0% This therapy is currently in Phase II development and is expected to launch in the US and 5EU in 2027 and 2028, respectively.

article thumbnail

Innovating for Individual Care: The Impact of USP on Personalized Medicine

Quality Matters

USP has a long-standing history of healthcare standards including those for compounding preparations that are tailored to meet the unique needs of patients who may not otherwise have access to their medications. DTx is projected to have a cumulative annual growth rate of up to 25.4% in the U.S.

article thumbnail

T2D market growth driven by novel GLP-1RAs and once-weekly basal insulin therapies

Pharmaceutical Technology

billion in 2029, with drug sales almost doubling at a compound annual growth rate (CAGR) of 11.5%. Specifically, across all the major classes there are significant developments, label updates, and biosimilar launches that are driving their growth. billion in sales in 2019, increasing to $136.2